AstraZeneca announced plans to expand its biologics manufacturing center in Frederick, Maryland with an investment of more than $200 million. The expansion of this project is expected to complete in mid-2017.
AstraZeneca’s Frederick biologics manufacturing center is an FDA licensed, large-scale cell culture production facility. The site currently produces a pediatric medication, as well as other investigational biologic products.
This project will increase production capacity at the facility to support AstraZeneca’s maturing pipeline, and will help position the company to keep pace with a growing demand for the development and use of biologics, which currently represent nearly 50% of AstraZeneca’s overall pipeline.
The expansion project will add approximately 40,000 additional square feet of manufacturing, laboratory and administrative space. The expansion is also expected to bring a total of 300 new jobs to the site.
